The Use and Interpretation of CommercialAPCGene Testing for Familial Adenomatous Polyposis
Open Access
- 20 March 1997
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 336 (12) , 823-827
- https://doi.org/10.1056/nejm199703203361202
Abstract
The use of commercially available tests for genes linked to familial cancer has aroused concern about the impact of these tests on patients. Familial adenomatous polyposis is an autosomal dominant disease caused by a germ-line mutation of the adenomatous polyposis coli (APC ) gene that causes colorectal cancer if prophylactic colectomy is not performed. We evaluated the clinical use of commercial APC gene testing.Keywords
This publication has 18 references indexed in Scilit:
- Pitfalls of Genetic TestingNew England Journal of Medicine, 1996
- Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility, Adopted on February 20, 1996.Journal of Clinical Oncology, 1996
- Commentary on the ASCO Statement on Genetic Testing for Cancer SusceptibilityJournal of Clinical Oncology, 1996
- The Use of Gene Tests to Detect Hereditary Predisposition to Cancer: Economic ConsiderationsJNCI Journal of the National Cancer Institute, 1995
- Genetic testing for children and adolescents. Who decides?JAMA, 1994
- Statement on use of DNA testing for presymptomatic identification of cancer risk. National Advisory Council for Human Genome ResearchPublished by American Medical Association (AMA) ,1994
- Identification of FAP Locus Genes from Chromosome 5q21Science, 1991
- Mutations of Chromosome 5q21 Genes in FAP and Colorectal Cancer PatientsScience, 1991
- Identification of deletion mutations and three new genes at the familial polyposis locusCell, 1991
- Identification and characterization of the familial adenomatous polyposis coli geneCell, 1991